Molecular Therapy rolls out open access and article deposition services for authors

The American Society of Gene Therapy and Nature Publishing Group (NPG) are pleased to announce the introduction of two new services to help authors comply with funder and institutional mandates for public access. Molecular Therapy now offers authors the option of immediate open access on publication, including deposition in PubMed Central, subject to the payment of a publication fee. In addition, as a further author benefit to aid compliance with several funding body mandates, Nature Publishing Group will deposit all Molecular Therapy articles to PubMed Central upon final publication, to be made public after 12 months.

Upon submission of original research articles, authors have the option of publishing their articles as open access for a publication fee of £2,000 / $3,000 / €2,400. Open access articles will be freely available upon publication. By paying this one-time fee, authors are also entitled to self-archive the final published PDF of their articles on a website, institutional repository, or other free public server upon publication. Open access articles will be designated by the MTOpen logo in both the print and online editions of the journal and will be freely accessible via PubMed Central immediately after publication.

Open access articles will be published under a Creative Commons license. Authors may choose between the Attribution-Noncommercial-No Derivative Works 3.0 Unported and the Attribution-Noncommercial-Share Alike 3.0 Unported Licence. The Attribution-Noncommercial-Share Alike Licence permits derivative works, ensuring that authors can comply with funders such as the Wellcome Trust. Under both licenses, the final published version of MTOpen articles can be downloaded and shared as long as the author and original publication are cited.

Under the terms of NPG’s License to Publish, self-archiving is encouraged on all original research articles published in Molecular Therapy. In all cases, the author’s version of the accepted manuscript can be made publicly accessible six months after publication. This applies regardless of whether the authors choose the MTOpen option.

Molecular Therapy (www.moleculartherapy.org) is the leading international journal for basic, translational, and clinical research aimed at the development of novel therapeutic approaches to treat disease. With a 2007 impact factor of 5.862 and an average review time of less than 3 weeks, Molecular Therapy is committed to publishing important peer-reviewed research and cutting-edge reviews and commentaries. Published by NPG, Molecular Therapy is the official journal of the American Society of Gene Therapy (ASGT).
Molecular Therapy joins *The EMBO Journal, EMBO reports* and *British Journal of Cancer*, which already offer an open access option to authors. NPG also announced today the introduction of an open access option on ten further journals. *Molecular Systems Biology*, published by NPG in partnership with the European Molecular Biology Organization, is a fully open access journal.

- ENDS -

**About Nature Publishing Group (NPG):**
Nature Publishing Group is a division of Macmillan Publishers Ltd, dedicated to serving the academic and professional scientific and medical communities. NPG’s flagship title, *Nature*, was first published in 1869. Other publications include *Nature* research journals, *Nature Reviews*, *Nature Clinical Practice* and a range of prestigious academic journals including society-owned publications. NPG also provides news content through *Nature News*. Scientific career information and free job postings are offered on *Naturejobs*.

NPG is a global company with principal offices in London, New York and Tokyo and offices in Basingstoke, Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Melbourne, Munich, Paris, San Francisco, Seoul and Washington DC. For more information, please go to [www.nature.com](http://www.nature.com).

**About The American Society of Gene Therapy**
The American Society of Gene Therapy (ASGT) was established in 1996 and has grown to more than 2000 members worldwide. The ASGT established *Molecular Therapy* in 2000, and it has become essential reading for those in the fields of molecular and cellular therapeutics and vaccination.

The ASGT is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene and related cell and nucleic acid therapies and the promotion of professional and public education. ASGT is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene therapies.